How Bittensor Is Reinventing Drug Discovery
In this episode, Ryan sits down with Micaela and Pedro, founders of Metanova Labs explaining how decentralized AI, crypto incentives, and adversarial competition are being used to screen billions of molecules and design better therapeutics.
What happens when drug discovery becomes a global AI competition? In this episode, Ryan sits down with Micaela and Pedro, founders of Metanova Labs — the first drug discovery subnet on Bittensor (Subnet 68).
They explain how decentralized AI, crypto incentives, and adversarial competition are being used to screen billions of molecules and design better therapeutics.
Metanova Labs turns virtual drug discovery into an open challenge. Miners submit molecule sets, nanobody sequences, and search algorithms. Validators score them. Models improve. The best candidates move toward wet-lab validation.
The team also announces a new partnership expanding into biologics, including nanobodies, allowing 50 top miner-generated candidates to move into in vitro testing. If you're interested in Bittensor, decentralized science, AI-driven biotech, longevity, or the future of drug discovery, this episode breaks it down clearly and practically.
Watch the episode.